🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT06141018
Active, not recruiting Not applicable

Effectiveness and Safety of Intra-articular SEMICAL GEL-B CROSS Therapy in Knee Osteoarthritis (SEM-ART1)

NCT06141018 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-01-15
Last updated
2025-08-21

Condition(s) studied

Knee Osteoarthritis

Investigational drug(s) / intervention(s)

Cross-linked intra-articular hyaluronic acidPlacebo

Cross-linked intra-articular hyaluronic acid: Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.

Placebo: Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.

Study summary

The goal of this clinical trial is to evaluate the effectiveness and safety of intra-articular injection of a cross-linked sodium hyaluronate; SEMICAL GEL-B CROSS, in knee osteoarthritis.

Primary objectives: The aim of this study is to obtain short- and long-term clinical data on the performance and safety of intra-articular injection of SEMICAL GEL B-CROSS, produced and marketed by Semical Biosurgery incorporated company, in knee osteoarthritis patients.

It is also aimed to monitoring known adverse events and complications, detecting previously unknown adverse events and complications, to identify and analyze emerging risks based on real-life data. Participants will receive intra-articular injection of either a cross-linked sodium hyaluronate (SEMICAL GEL-B CROSS); or placebo (isotonic saline solution) at baseline, and will be followed-up for one year to compare the effectiveness and safety of the given therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 and over, both male and female * Diagnosed with clinical knee osteoarthritis according to the American College of * Rheumatology (ACR) criteria, with Kellgren \& Lawrence stage II and III osteoarthritic findings on antero-posterior knee radiographs * Able to provide written informed consent Exclusion Criteria: \-

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Antalya Training and Research Hospital Antalya Turkey (Türkiye)

More Semikal Technology trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06141018 on ClinicalTrials.gov ↗ ← All trials in Turkey